Patents by Inventor Maurizio Pellecchia

Maurizio Pellecchia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20050112716
    Abstract: Methods for rapidly identifying drug candidates that can bind to an enzyme at both a common ligand site and a specificity ligand site, resulting in high affinity binding. The bi-ligand drug candidates are screened from a focused combinatorial library where the specific points of variation on a core structure are optimized. The optimal points of variation are identified by which atoms of a ligand bound to the common ligand site are identified to be proximal to the specificity ligand site. As a result, the atoms proximal to the specificity ligand site can then be used as a point for variation to generate a focused combinatorial library of high affinity drug candidates that can bind to both the common ligand site and the specificity ligand site. Different candidates in the library can then have high affinity for many related enzymes sharing a similar common ligand site.
    Type: Application
    Filed: July 2, 2004
    Publication date: May 26, 2005
    Inventors: Daniel Sem, Maurizio Pellecchia, Anna Tempczyk-Russell
  • Publication number: 20050042674
    Abstract: The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand which compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.
    Type: Application
    Filed: February 21, 2002
    Publication date: February 24, 2005
    Inventors: Lin Yu, Qing Dong, Fabrice Pierre, Edcon Chang, Hengyuan Lang, Yong Qin, Yunfeng Fang, Mark Hansen, Maurizio Pellecchia
  • Publication number: 20050027000
    Abstract: The present invention provides a method for treating cancer in a mammal comprising contacting the cancer cells with a compound which is a apogossypol, derivative.
    Type: Application
    Filed: June 25, 2004
    Publication date: February 3, 2005
    Inventors: John Reed, Maurizio Pellecchia
  • Publication number: 20050019825
    Abstract: The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand that compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.
    Type: Application
    Filed: March 15, 2002
    Publication date: January 27, 2005
    Inventors: Qing Dong, Fabrice Pierre, Hengyuan Lang, Lin Yu, Mark Hansen, Daniel Sem, Maurizio Pellecchia
  • Patent number: 6797460
    Abstract: Methods for rapidly identifying drug candidates that can bind to an enzyme at both a common ligand site and a specificity ligand site, resulting in high affinity binding. The bi-ligand drug candidates are screened from a focused combinatorial library where the specific points of variation on a core structure are optimized. The optimal points of variation are identified by which atoms of a ligand bound to the common ligand site are identified to be proximal to the specificity ligand site. As a result, the atoms proximal to the specificity ligand site can then be used as a point for variation to generate a focused combinatorial library of high affinity drug candidates that can bind to both the common ligand site and the specificity ligand site. Different candidates in the library can then have high affinity for many related enzymes sharing a similar common ligand site.
    Type: Grant
    Filed: August 15, 2001
    Date of Patent: September 28, 2004
    Assignee: Triad Therapeutics, Inc.
    Inventors: Daniel S. Sem, Maurizio Pellecchia, Anna Tempczyk-Russell
  • Publication number: 20040132102
    Abstract: Methods of detecting interactions of a putative ligand with a selectively labeled target molecule, methods of screening for compounds which bind to a selectively labeled target molecule, methods for calculating the dissociation constant of a ligand that binds to a selectively labeled target molecule, and methods to determine the specific amino acids of a target molecule affected by the binding of a ligand, as well as compounds identified by these screening methods, are provided.
    Type: Application
    Filed: October 15, 2003
    Publication date: July 8, 2004
    Inventor: Maurizio Pellecchia
  • Publication number: 20040009526
    Abstract: The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand which compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.
    Type: Application
    Filed: February 21, 2002
    Publication date: January 15, 2004
    Inventors: Lin Yu, Qing Dong, Fabrice Pierre, Edcon Chang, Hengyuan Lang, Yong Qin, Yunfeng Fang, Mark Hansen, Maurizio Pellecchia
  • Publication number: 20040009527
    Abstract: The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand that compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.
    Type: Application
    Filed: March 15, 2002
    Publication date: January 15, 2004
    Inventors: Qing Dong, Fabrice Pierre, Hengyuan Lang, Lin Yu, Mark Hansen, Daniel S. Sem, Maurizio Pellecchia
  • Patent number: 6620589
    Abstract: Methods for rapidly identifying drug candidates that can bind to an enzyme at both a common ligand site and a specificity ligand site, resulting in high affinity binding. The bi-ligand drug candidates are screened from a focused combinatorial library where the specific points of variation on a core structure are optimized. The optimal points of variation are identified by which atoms of a ligand bound to the common ligand site are identified to be proximal to the specificity ligand site. As a result the atoms proximal to the specificity ligand site can then be us ed as a point for variation to generate a focused combinatorial library of high affinity drug candidates that can bind to both the common ligand site and the specificity ligand site. Different candidates in the library can then have high affinity for many related enzymes sharing a similar common ligand site.
    Type: Grant
    Filed: June 2, 2000
    Date of Patent: September 16, 2003
    Assignee: Traid Therapeutics, Inc.
    Inventors: Daniel S. Sem, Maurizio Pellecchia, Anna Tempczyk-Russell
  • Publication number: 20030113751
    Abstract: The invention provides a method for obtaining a binding compound for a protein family, wherein the members of the protein family bind a common ligand. The method includes the steps of (a) providing a sample containing a protein from the protein family, a first ligand and a second ligand under conditions wherein the first ligand, the second ligand and the protein form a bound complex; (b) detecting magnetization transfer between the first ligand and the second ligand in the bound complex, thereby determining that the two ligands are proximal in the bound complex; and (c) obtaining a candidate binding compound including the first ligand, or a fragment thereof linked to the second ligand, or a homolog thereof, whereby the population contains binding compounds that bind to members of the protein family.
    Type: Application
    Filed: June 13, 2002
    Publication date: June 19, 2003
    Inventors: Daniel S. Sem, Maurizio Pellecchia, Qing Dong, Mark Kelly, Min S. Lee
  • Publication number: 20030008326
    Abstract: The invention provides a method for determining a structure model for a test ligand bound to a macromolecule binding site. Structural constraints for the test ligand are derived from spectroscopic signals arising from interactions between the test ligand and macromolecule. The structure constraints are used as constraints in docking a structure model of the ligand to a structure model of the macromolecule, or as constraints in overlaying a structure model of the test ligand on the known structure for a reference ligand that binds to the macromolecule. The invention further provides a method for determining a structure model for a macromolecule bound to a ligand. Structural constraints derived from spectroscopically observed interactions of the macromolecule and a reference ligand are used to guide molecular modeling or to evaluate the results of a molecular modeling simulation of the macromolecule.
    Type: Application
    Filed: May 30, 2002
    Publication date: January 9, 2003
    Inventors: Daniel S Sem, Maurizio Pellecchia
  • Publication number: 20020127731
    Abstract: A method for preferentially observing an exposed position (1c) of a macromolecule. A sample is obtained having a macromolecule (1a) with a first proton (1) and a second molecule (2a) with a second proton (2); then applying a magnetic field (4) to the sample and irradiating the sample with a pulse sequence (5) that preferentially demagnetizes protons of the macromolecule (1, 3) relative to the second proton (2); allowing the second proton (2) to exchange (6) with an exposed proton (1) of the macromolecule; and detecting the magnetization from the relatively magnetized second proton (2), which is now bound to the exposed position (1c) of the macromolecule. The invention also provides a method for observing a position in the macromolecule that bind a ligand.
    Type: Application
    Filed: December 19, 2001
    Publication date: September 12, 2002
    Inventors: Daniel S. Sem, Maurizio Pellecchia
  • Publication number: 20020028468
    Abstract: Methods for rapidly identifying drug candidates that can bind to an enzyme at both a common ligand site and a specificity ligand site, resulting in high affinity binding. The bi-ligand drug candidates are screened from a focused combinatorial library where the specific points of variation on a core structure are optimized. The optimal points of variation are identified by which atoms of a ligand bound to the common ligand site are identified to be proximal to the specificity ligand site. As a result, the atoms proximal to the specificity ligand site can then be used as a point for variation to generate a focused combinatorial library of high affinity drug candidates that can bind to both the common ligand site and the specificity ligand site. Different candidates in the library can then have high affinity for many related enzymes sharing a similar common ligand site.
    Type: Application
    Filed: August 15, 2001
    Publication date: March 7, 2002
    Applicant: TRIAD THERAPEUTICS, INC.
    Inventors: Daniel S. Sem, Maurizio Pellecchia, Anna Tempczyk-Russell